Navigation Links
FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
Date:6/16/2010

WASHINGTON, June 16 /PRNewswire-USNewswire/ -- Tomorrow, the Food and Drug Administration (FDA) will hold a hearing to consider approval of a new drug application for an abortifacient drug, ulipristal acetate, as an emergency contraceptive, or a new "Plan B."

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO)

Jeanne Monahan, Family Research Council's Director for the Center for Human Dignity, released the following statement urging the FDA to reject the drug application:

"The drug manufacturer's application is very misleading because the chemical makeup of ulipristal is almost identical to mifepristone, popularly known as RU-486, which is primarily an abortifacient. While the drug can act in a way that inhibits ovulation, it also can act as an abortifacient.

"Women deserve to know the truth about drugs that are marketed to them, and the effects the drugs may have on their health and well-being. The FDA must seriously consider the adverse health effects the drug could have on women, in particular infection and severe bleeding as has been seen with RU-486.

"In the words of the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), 'Ulipristal acetate is an abortifacient of the same type as mifepristone (RU-486) and... its approval as an emergency contraceptive raises serious health and ethical issues. Furthermore, ulipristal's potential effects on women who used the drug off-label and upon ongoing pregnancies are essentially unexamined and untested.'

"Both ulipristal and mifepristone block the key early pregnancy hormone, progesterone, from functioning properly which effectively starves the embryo. That action potentially can interfere with or end an established pregnancy.

"Women deserve to know what the drug is doing in their body. Preventing human life from beginning is not the same as destroying a life that has already begun. And to many women it is a distinction that makes all the difference.

"We urge the FDA to take seriously its role to protect innocent human life and safeguard the health of American women by rejecting this abortion drug. We also urge a thorough review process to ensure that women's health is not jeopardized just to advance the agenda of the abortion industry."


'/>"/>
SOURCE Family Research Council
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
2. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
3. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
4. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
5. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
6. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
7. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
8. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
9. DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat
10. McCaughey Urges Use of First NYS Hospital Infection Report
11. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... 2016   Genomic Health, Inc. (Nasdaq: GHDX ) ... year ended December 31, 2015. --> ... 2015, compared with $69.1 million in the fourth quarter of 2014, ... increased 9 percent compared with the same period in the prior ... was $63.9 million in the fourth quarter of 2015, an increase ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... and updated its hallmark resource, Infusion Therapy Standards of Practice, to include vascular ... vein illumination with an estimated 85% share of the market, facilitates adherence to ...
(Date:2/11/2016)... ... 11, 2016 , ... Dickinson Insurance & Financial Services continues their commitment to ... support of a local boy named Barrett, who has been fighting ALL leukemia for ... rally support for, all local families dealing with childhood cancer. Information on how to ...
(Date:2/11/2016)... ... 11, 2016 , ... Be Well Medical Group (Be Well) is ... Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group ... in the convenience of their homes, offices or at the practices’ local office. It ...
(Date:2/11/2016)... ... ... Husted Kicking has completed its Third Annual Husted Kicking College ... 2016 according to kicking coach Michael Husted. , “This event serves as an official ... Indianapolis,” says Husted. “The NFL uses a third party organization to select players for ...
Breaking Medicine News(10 mins):